The US Food and Drug Administration has granted accelerated approval to tarlatamab-dlle (Imdelltra, Amgen) for extensive-stage small cell lung cancer (SCLC) with disease progression on or after platinum-based chemotherapy. Tarlatamab is a first-in-class bispecific T-cell engager (BiTE) that binds delta-like ligand 3 on the surface of cells, including tumor cells, and CD3 expressed on the surface of T-cells. It causes T-cell activation, release of inflammatory cytokines, and lysis of DLL3-expressing cells, according to labeling. Approval was based on data from 99 patients in DeLLphi-301 trial with relapsed/refractory extensive-stage SCLC who had progressed after platinum-based chemotherapy Patients with symptomatic brain metastases, interstitial lung disease, noninfectious pneumonitis, and active immunodeficiency were excluded. The overall response rate was 40%, and median duration of response 9.7 months. The overall response rate was 52% in 27 patients with platinum-resistant SCLC and 31% in 42 with platinum-sensitive disease. Continued approval may depend on verification of clinical benefit in a confirmatory trial. Labeling includes a box warning of serious or life-threatening cytokine release syndrome and neurologic toxicity, including immune effector cell-associated neurotoxicity syndrome. The most common adverse events, occurring in 20% or more of patients, were cytokine release syndrome, fatigue, pyrexia, dysgeusia, decreased appetite, musculoskeletal pain, constipation, anemia, and nausea. The most common grade 3 or 4 laboratory abnormalities included decreased lymphocytes, decreased sodium, increased uric acid, decreased total neutrophils, decreased hemoglobin, increased activated partial thromboplastin time, and decreased potassium. The starting dose is 1 mg given intravenously over 1 hour on the first day of the first cycle followed by 10 mg on day 8 and day 15 of the first cycle, then every 2 weeks until disease progression or unacceptable toxicity.

Thank you so much Dr kim! ❤️❤️❤️

Dr is there any merit to Dr Thomas Seyfried approach to starving cancer by depriving it of glucose and glutamine.

Is immunotherapy doable in case of Hodgkin lymphoma ?

Thank you Doctor

감사합니다. 남편이 Vrd로 치료시작했습니다. D-vdt 로 할줄알았는데 Vrd로 하신다네요. 어떤 차이점이 있을까요?

I am heterozygous for H63D, my entire family on my mother's line has hemochromatosis, so in some way we inherit it dominantly. I was diagnosed at 38 years old, with 1200 ferritin and a saturation of 50%, 90umol/g of iron in the liver.

Thank you sir your lecture helped understand the process of investigation

Thank you for your time to produce this video Dr. Kim. I am on Pembro for a year for 911 related throat cancer. I am being treated at Sloan Kettering. I had a laryngectomy. This is my second bout with the squamous cell carcinoma. The only reaction I had was the rash and itching. Again thank you Dr. Kim.

New bispecific T cell Engager (BiTE) for SCLC In May 2024, the FDA has granted accelerated approval to tarlatamab-dlle (Imdelltra, Amgen) for extensive-stage small cell lung cancer (SCLC) with disease progression on or after platinum-based chemotherapy. Tarlatamab is a first-in-class bispecific T-cell engager (BiTE) that binds delta-like ligand 3 on the surface of cells, including tumor cells, and CD3 expressed on the surface of T-cells. It causes T-cell activation, release of inflammatory cytokines, and lysis of DLL3-expressing cells. Approval was based on data from 99 patients in DeLLphi-301 trial with relapsed/refractory extensive-stage SCLC who had progressed after platinum-based chemotherapy Patients with symptomatic brain metastases, interstitial lung disease, noninfectious pneumonitis, and active immunodeficiency were excluded. The overall response rate was 40%, and median duration of response 9.7 months. The overall response rate was 52% in 27 patients with platinum-resistant SCLC and 31% in 42 with platinum-sensitive disease. Continued approval may depend on verification of clinical benefit in a confirmatory trial. Labeling includes a box warning of serious or life-threatening cytokine release syndrome and neurologic toxicity, including immune effector cell-associated neurotoxicity syndrome. The most common adverse events, occurring in 20% or more of patients, were cytokine release syndrome, fatigue, pyrexia, dysgeusia, decreased appetite, musculoskeletal pain, constipation, anemia, and nausea. The most common grade 3 or 4 laboratory abnormalities included decreased lymphocytes, decreased sodium, increased uric acid, decreased total neutrophils, decreased hemoglobin, increased activated partial thromboplastin time, and decreased potassium. The starting dose is 1 mg given intravenously over 1 hour on the first day of the first cycle followed by 10 mg on day 8 and day 15 of the first cycle, then every 2 weeks until disease progression or unacceptable toxicity.

Thank you for your video and for the Psalm at the end. God Bless!

My red blood cells count is 5.13 is that normal?

Show me the data on super saturation… I want to see your data on 1,000+mg doses. ER+ BC can usually be knocked out in less than 6mo using 2,000mg CBD and 1,000mg RSO per day. Similar to bone cancers and brain cancers.

PS per Cristina Sanchez… THC kills every single cancer type in a dose dependent manor. The exception is certain brain tumors that are in the midbrain like DIPG. There is not one cancer that is made worse by Cannabinoids, that has been confirmed also by scientists at HU. Hahaha this doctor is using wayyyy too many old and political studies. 2019 or newer. Sativex and Epidiolex are garbage medicines.

I have met and watched multiple people use Cannabinoids only and walk away cancer free. My success rate is currently 100% on cancers, with 4 people currently using proper dosages. Matter of time before their results become available. The problem is these doctors want to ignore the fact that there is no overdose, it is a dose dependent treatment. I have seen pancreatic cancer patients need 3,000mgs of RSO per day while most need far less. It also isn’t just THC either, almost all known Cannabinoids have anti-cancer properties. It is always best to use large doses of both. As for cardio effects, the act of smoking is dangerous no matter which drug you choose. This is how people damage their endothelial cells with Cannabis. People should be ingesting, taking sublingually, transdermally or via suppository. This video doesn’t even scratch the surface of Cannabinoid medicine. Hahahaha this dr obviously has a lot of money invested in big pharma, half of these stats have been proven incorrect. I’ve read almost every study he is talking about, the data is crap. And most of these scary sounding side effects are minor and temporary, often times not even seen. Hahaha haha gateway drug? That isn’t what state wide studies show on Opioid use after Cannabis legalization… every single time. Hahaha hahaha I take anywhere between 500-1,000mgs of THC per day… everyone of my biomarkers that were in the red… went into the green. My blood pressure is also down. Hahaha after my second Cauda Equina Surgery, I was up to 7,000mg of THC per day for a few weeks, dropped down to 3,000mg once the pain calmed down…. Took multiple breaks with the only withdrawal symptom being 1 or 2 days struggling to fall asleep. Nada. Plus we know how to treat CHS, which is about the only actual direct danger associated with Cannabis use.

In November 2023, the FDA approved pembrolizumab + chemo (FP or CAPOX) for advanced/metastatic HER2(-) gastric or GEJ adenocarcinoma. When compared with chemo + placebo, improved OS (12.9 vs. 11.5 mon) and ORR 51 vs42%. www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-pembrolizumab-chemotherapy-her2-negative-gastric-or-gastroesophageal-junction

14프로 이상의 다발 골수종 환자가 20년 이상 장기생존 하신다고 하셨는데. 전부 항암치료 후 그렇게 지내시는건 가요? 아니면 치료 하지 않고 그냥 내버려둬도 그렇게 돤다는 말씀 이신가요??

How to prevent from Immune Thrombocytopenia forever click the link below 👇 kzfaq.info/get/bejne/r7WEdsJ6tcjWnmg.htmlsi=0laN6vlLBLKUtEpk

Hello doc I have polycythemia it's now 3 years how can I contact you,thank you in advance.

Thank you Dr.

New published report showed cannabis law for recreational use didn’t affect the use of opioids and opioid use related mortality. jamanetwork.com/journals/jama-health-forum/fullarticle/2813866

👍 very well explained

Why no mention of Keytruda for right side colon cancer?

Is NSCLC squamous cell HPV+ second primary tumor in both lungs and mediastinum curable ?

you said i had lymph nodes infected in lower back. shows up on test i took.could it b bladder cancer? listen to doctors talk about finding and treating it. there’s bladder testing,blood tests and lymph nodes testing removing bladder and replacing with another item. with immunotherapies they have 70%sucess rate or more. just listen to this pop cast.

I wish my state had “Dying with Dignity” legislation passed.

IF YOU HAVE CANCER CK OUT JOE TIPPENS CANCER PROTOCOL FENBENDAZOLE RIGHT AWAY, FENBENDAZOLE REDUCES AND KILLS CANCER CELLS WITH OUT ANY SIDE EFFECTS. AND CAN BE USED AS A PROPHYLACTIC AGAINST CANCER. NOT HARD TO USE, WHAT HAVE YOU GOT TO LOSE. JESUS LOVES YOU ❤❤❤

This is great

Thanks for reaching for help I from Cape town South Africa my husband died November 2023 he was diagnosed with COVID pneumonia reading his biopsy results he had lung cancer he was diagnosed by pulmonigist at a private hospital he smoke and his parents died of lung cancer his Dr refuse to show me his full blood count results and diff count results I am a medical results officer 28 years don't know treatment but can read results I would like to to get closer for our children he lived on oxygen private hospital and Dr's don't know how hard it is family I expect it but not the children how many private hospital and Dr's pulmonigist take a a oath for granted bless you

I recently found out I am heterozygous H63D with Pro570Ser? I have 125% Iron sat low tibc and normal range of ferritin. Have joint pain muscle pains primarily in my calves and sometimes my thighs. It’s rough. I’m still eating for my first appointment with my hematologist/oncologist.

Thanks so much, very informative

In October of 2023I was diagnosed with nsc stage 4 lung cancer which spread to the brain. I was in the hospital for three weeks and had ten rounds on brain radiation. In December i started chemo and immunotherapy. I just finished my sixth treatment last week. I'm taking Keytruda, Alimta and Carboplatin. I went for a MRI and CT scan in February and the oncologist had good news for me. Everything is shrinking and there is no new growth and nothing is spreading. Now I'm taking Keytruda and Alimta for the next 12 months after that it will just be Keytruda for the next 12 months after that. I've had no major side effects other than slight change in taste and slight appetite change. I'm still eating but not the same foods as before. I'm hoping for continued success with this treatment. The nodule they originally found on my right lung in October was 1.5cm.

Thank you so much for your informative lectures our professor ❤.. I’m Egyptian Surgical oncologist, hope to find a lecture about sarcoma by your my preferred way in explanation . Many thanks for helping us to understand and be updated our professor.❤

Great Lectures ❤

Thank you for this wonderful video. Would you be able to tell me if immunotherapy would be an option for a late stage cancer patient with an autoimmune disease (colitis)? If so what precautions would need to be taken and what symptoms would need to be looked out for?

Dear Dr. Kim, I have stage 3B large cell neuroendocrine lung cancer. I finished chemo (5 rounds etoposide and carboplatin) and 6 weeks of concurrent radiation. I had good response to this but of course not total remission. Now the only thing I am being offered next is Imfinzi. I did not have any PD-L1 expression found on my tumor sample. I am told that I do not have any mutations or markers found for targeted therapy or immunotherapy. Do you think that Imfinzi makes any sense for me? I am of course desperate to do something besides waiting for my cancer to grow back and spread to other areas of my body. Thank you for your information here and any opinion you have for me.

Love these Lectures, very helpful for trainees--Thank you Dr. Kim

I`m not the type of person that write testimonials❤ but I feel like I really need to give thanks to this #DrAdigba treatment solution herbal regarding how effective these medicines are. I observed a big development right after just 2 weeks. This early morning, the Herpes were almost unseen as well as cured……

Bonjour, est-ce que l'olaparib est plus efficace en association avec des compléments alimentaires comme la vitamine C liposomal ? Je reçois de l'olaparib et du beva Merci

Thank you so much doctor. Very informative.

Thank you for your information. I carry C282Y variants A/A and H63D C/C, DX 2020 w/Autoimmune hemolytic anemia & cold agglutinins (polyclonal).. 2023 Labs: Ferritin 634; Iron 199; TIBC 219; Iron sat% 91. (Increased Fe/iron labs first noted increase in 2020). Hgb & RBC stable at just below normal levels. How would you know if the high Fe/iron is from Hemochromatosis or the anemia?

교수님 림사랑에서 ebv관련글 잘 보았습니다 저희아이가 ebv로 t세프림프종과 hlh이 왔습니다 항암중 부작용이 심하게 와 옵디보(키트루다와같은기전으로알고있습니다)쓰려고 하고 있습니다 그런데 몇일전 스테로이드를 낮추는 과정에서 간수치가 7천까지 올라 간부전까지 올 수있는 위험한 상황이였어요 낮추면 열이 오른다거나 하는 순간은 많았습니다 다행히 고용량스테이로이로 위험한 순간은 넘겼지만 .. 신장투석으로 중환자실에 있습니다 옵디보를 몆일 안으로 사용하려 하는거 같은데 옵디보를 사용할 시 스테로이드를 끊어야 하는 상황에서 hlh이나 ebv가 얼마나 위험한 상황까지 갈 수도 있지 않을까 의료진들도 폭풍이 올거라고 무서운얘기만 했습니다 너무 두렵습니다 1회치료로 어느정도 효과가 있다면 너무 감사하겠지만 그러지 못하면 저번같은 간부전 상황까지 올까봐 너무 두렵습니다 11살딸아이입니다 혹시 의견들을수 있을까 유투브에 글남겨봅니다 간절한 마음으로 남겨봅니다

Thank-you doctor !! I am so happy I found you ...

ECHELON-1 trial update analysis for young adults (age 15-39): Brentuximab + AVD is better than AVBD in 6-yr- DFS and OS in young adults (age 15-39). docs.adcetris.com/haematologica-ECHELON-1-AYA-e-pub.pdf?dclid=CL3Kp6qSiIUDFfj8_QUdGokFgw

Thanks 🙏

Dear Dr.Stanley Kim, My mom was diagnosed with stage 4 metastatic non-small cell lung cancer NSCLC back in August 2020. Today, it's been 11 months since she started with Tagrisso. My question is, What's after Tagrisso? Is there any news on this matter? Any insights from you would be appreciated.

The US Food and Drug Administration (FDA) has approved tislelizumab-jsgr (Tevimbra, BeiGene, Ltd.) as second-line monotherapy for certain adult patients with unresectable or metastatic esophageal squamous cell carcinoma (ESCC). Specifically, the novel checkpoint inhibitor is approved for patients with ESCC after prior systemic chemotherapy that did not include a programmed death-ligand 1 (PD-L1) inhibitor. Approval was based on findings from the open-label, phase 3 RATIONALE 302 trial showing a statistically significant and clinically meaningful overall survival benefit with tislelizumab vs investigator's choice of chemotherapy. Study participants included 512 adults enrolled at 123 research sites in 11 countries in Europe, Asia, and North America. Patients were randomly assigned to receive intravenous tislelizumab, a humanized immunoglobulin G4 anti-programmed cell death protein 1 monoclonal antibody, at a dose of 200 mg every 3 weeks or investigator's choice of standard chemotherapy with paclitaxel, docetaxel, or irinotecan until disease progression, unacceptable toxicity, or study withdrawal. Median overall survival in the intention-to-treat population, the primary study endpoint, was 8.6 months vs 6.3 months in the chemotherapy arms (hazard ratio [HR], 0.70). The survival benefit was observed across predefined subgroups, including baseline PD-L1 status and region. The new agent was also associated with improved overall response rate (20.4% vs 9.8%) and more durable response (median duration of response of 7.1 vs 4.0 months; HR, 0.42) compared with chemotherapy. The most common adverse reactions for tislelizumab, each occurring in at least 20% of treated patients, included increased glucose and decreased hemoglobin, lymphocytes, sodium, and albumin as well as increased alkaline phosphatase, anemia, fatigue, increased aspartate aminotransferase, musculoskeletal pain, decreased weight, increased alanine aminotransferase, and cough. Fewer patients in the tislelizumab arm experienced grade 3 or greater treatment-emergent adverse events compared with the chemotherapy arm (46% vs 68%, respectively), and fewer patients discontinued tislelizumab vs chemotherapy due to such an event (7% vs 14%).

The US Food and Drug Administration (FDA) has approved tislelizumab-jsgr (Tevimbra, BeiGene, Ltd.) as second-line monotherapy for certain adult patients with unresectable or metastatic esophageal squamous cell carcinoma (ESCC). Specifically, the novel checkpoint inhibitor is approved for patients with ESCC after prior systemic chemotherapy that did not include a programmed death-ligand 1 (PD-L1) inhibitor. Approval was based on findings from the open-label, phase 3 RATIONALE 302 trial showing a statistically significant and clinically meaningful overall survival benefit with tislelizumab vs investigator's choice of chemotherapy. Study participants included 512 adults enrolled at 123 research sites in 11 countries in Europe, Asia, and North America. Patients were randomly assigned to receive intravenous tislelizumab, a humanized immunoglobulin G4 anti-programmed cell death protein 1 monoclonal antibody, at a dose of 200 mg every 3 weeks or investigator's choice of standard chemotherapy with paclitaxel, docetaxel, or irinotecan until disease progression, unacceptable toxicity, or study withdrawal. Median overall survival in the intention-to-treat population, the primary study endpoint, was 8.6 months vs 6.3 months in the chemotherapy arms (hazard ratio [HR], 0.70). The survival benefit was observed across predefined subgroups, including baseline PD-L1 status and region. The new agent was also associated with improved overall response rate (20.4% vs 9.8%) and more durable response (median duration of response of 7.1 vs 4.0 months; HR, 0.42) compared with chemotherapy. The most common adverse reactions for tislelizumab, each occurring in at least 20% of treated patients, included increased glucose and decreased hemoglobin, lymphocytes, sodium, and albumin as well as increased alkaline phosphatase, anemia, fatigue, increased aspartate aminotransferase, musculoskeletal pain, decreased weight, increased alanine aminotransferase, and cough. Fewer patients in the tislelizumab arm experienced grade 3 or greater treatment-emergent adverse events compared with the chemotherapy arm (46% vs 68%, respectively), and fewer patients discontinued tislelizumab vs chemotherapy due to such an event (7% vs 14%).

Neoadjuvant immunochemotherapy with durvalumab x 4 cycles before surgery for NasCLC stages II-IIIB showed improved complete pathological response and disease free survival. This is similar to nivolumab study I described in the lecture above. But the cPR rate of 17% appears slightly lower than that of nivolumab. www.nejm.org/doi/full/10.1056/NEJMoa2304875

Corrections: 1. At 2:16, I said 5cm, but it should be 5 mm. 2. At 32:17, regarding intermittent therapy, I said some patients may take chemotherapy free time of several month or a year. But I should have said several months out of a year.